Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
January 29, 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
January 29, 2024 02:00 ET
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
December 14, 2023 04:00 ET
|
AKAMPION
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
Vidac Pharma présente des résultats in vitro démontrant la compatibilité de VDA 1275 avec des agents chimiothérapeutiques classiques
November 29, 2023 01:00 ET
|
Vidac Pharma Holding PLC
Un nouveau régulateur du métabolisme des cellules cancéreuses bientôt à l’étude en vue d’une obtention d’une autorisation de mise sur le marché (IND) Londres (Royaume-Uni), Rehovot (Israël), 29...
Vidac Pharma reports in vitro results showing VDA-1275 compatible with classical chemotherapy
November 29, 2023 01:00 ET
|
Vidac Pharma Holding PLC
Novel cancer cell metabolism regulator to progress into IND enabling studies London (UK), Rehovot (Israel), 29 November 2023, 7:00 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
November 13, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...
Neoantigen Cancer Vaccine Market Size is Projected to Reach $1.38 billion by 2030: Straits Research
October 26, 2023 15:00 ET
|
Straits Research
New York, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Neoantigens that arise from cancer-specific mutations are an additional class of antigens that are desirable for therapeutic cancer...
Triple-Negative Breast Cancer Treatment Market Size to Surpass US$ 20 Billion by 2030
September 25, 2023 14:45 ET
|
Zion Market Research
NEW YORK, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Triple-Negative Breast Cancer Treatment Market By Drug Type...
Antibody Drug Conjugates Market to increase by USD 34.7 Billion by 2032 || North America led with a 40% revenue share in 2022
September 25, 2023 09:23 ET
|
Market.Us
New York, Sept. 25, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Antibody Drug Conjugates Market size is expected to be worth around USD 34.7 Billion by 2032 from...
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
September 19, 2023 04:00 ET
|
AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...